<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24657236</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>03</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>11</Month>
            <Day>19</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-9629</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>28</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pulmonary pharmacology &amp; therapeutics</Title>
                <ISOAbbreviation>Pulm Pharmacol Ther</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.</ArticleTitle>
            <Pagination>
                <MedlinePgn>149-53</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pupt.2014.03.003</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1094-5539(14)00035-2</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">When first approved in the European Union (EU), the omalizumab dosing table had upper bodyweight and IgE limits of 150 kg and 700 IU/mL, respectively. In this study, we assessed the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of omalizumab in patients with IgE/bodyweight combinations above those in the original dosing table.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A multicentre, open-label, parallel-group study assessed the safety, PK and PD of omalizumab in 32 patients with mild-to-moderate allergic (IgE-mediated) asthma. Patients received two subcutaneous injections of omalizumab at one of three dosage levels (450, 525, or 600 mg), chosen according to baseline IgE (300-2000 IU/mL) and bodyweight (40-150 kg), with a 14-day interval between injections.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 69 adverse events (AEs), none of them serious, were reported by 26 (81.3%) patients. Analysis of laboratory measurements, vital signs and ECG data revealed no adverse findings of clinical relevance. The PK profile was consistent with previous data for lower doses. Mean maximum decrease of free IgE from screening was ≥99% for all three doses, and mean free IgE concentrations remained &lt;25 ng/mL for at least 2 weeks after the second dose. The reductions in free IgE were consistent with levels previously associated with clinical improvements.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The safety and PK/PD findings from this study are consistent with previous data, and supported the extension of the omalizumab dosing table to include those patients with higher IgE/bodyweight combinations. Clinical trial registry and registration number: clinicaltrials.gov (NCT00546143).</AbstractText>
                <CopyrightInformation>Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kornmann</LastName>
                    <ForeName>Oliver</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pulmonary Department, Internal Medicine, University Hospital Mainz, Langenbeckstraße 1, 55131 Mainz, Germany. Electronic address: kornmann@ikf-pneumologie.de.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Watz</LastName>
                    <ForeName>Henrik</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pulmonary Research Institute at LungenClinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research, Grosshansdorf, Germany. Electronic address: H.Watz@pulmoresearch.de.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fuhr</LastName>
                    <ForeName>Rainard</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>PAREXEL International GmbH, Klinikum Westend, Haus 17, D-14050 Berlin, Germany. Electronic address: Rainard.Fuhr@parexel.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krug</LastName>
                    <ForeName>Norbert</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fraunhofer Institut für Toxikologie und Experimentelle Medizin, Nikolai-Fuchs-Str. 1, 30625 Hannover, Germany. Electronic address: norbert.krug@item.fraunhofer.de.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Erpenbeck</LastName>
                    <ForeName>Veit J</ForeName>
                    <Initials>VJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Novartis Pharma AG, Basel, Switzerland. Electronic address: veit.erpenbeck@novartis.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaiser</LastName>
                    <ForeName>Guenther</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Novartis Pharma AG, Basel, Switzerland. Electronic address: guenther.kaiser@novartis.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT00546143</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>03</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Pulm Pharmacol Ther</MedlineTA>
            <NlmUniqueID>9715279</NlmUniqueID>
            <ISSNLinking>1094-5539</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018927">Anti-Asthmatic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000888">Antibodies, Anti-Idiotypic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2P471X1Z11</RegistryNumber>
                <NameOfSubstance UI="D000069444">Omalizumab</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>37341-29-0</RegistryNumber>
                <NameOfSubstance UI="D007073">Immunoglobulin E</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018927" MajorTopicYN="N">Anti-Asthmatic Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000888" MajorTopicYN="N">Antibodies, Anti-Idiotypic</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001249" MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007073" MajorTopicYN="N">Immunoglobulin E</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069444" MajorTopicYN="N">Omalizumab</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Bodyweight</Keyword>
            <Keyword MajorTopicYN="N">IgE</Keyword>
            <Keyword MajorTopicYN="N">Omalizumab</Keyword>
            <Keyword MajorTopicYN="N">PK/PD</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>03</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>03</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>3</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24657236</ArticleId>
            <ArticleId IdType="pii">S1094-5539(14)00035-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pupt.2014.03.003</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>